Julie Wilson1,2, Barry Wright3,4, Sandra Jost4,5, Robert Smith6, Helen Pearce7, Sally Richardson8. 1. Department of Mathematics, University of York, York, UK. 2. Department of Chemistry, University of York, York, UK. 3. Hull York Medical School, University of York, York, UK. 4. Leeds and York Partnership NHS Foundation Trust, Leeds, UK. 5. Department of Health Science, University of York, York, UK. 6. York Teaching Hospital NHS Foundation Trust, York, UK. 7. Tees, Esk and Wear Valleys NHS Foundation Trust, Middlesbrough, UK. 8. University College Hospital, London, UK.
Abstract
BACKGROUND: An increase in urinary indolyl-3-acryloylglycine (IAG) has been reported in children with autism spectrum disorders (ASD) who suffer with bowel problems in comparison to ASD children without gastrointestinal (GI) problems. The case for dietary intervention for ASD children with GI symptoms might be strengthened were such a difference to be autism-specific. METHODS: Quantitative analysis of urinary IAG levels was performed for 53 children on the autism spectrum and 146 age-matched controls. The parents of each child were asked to provide information on bowel symptoms experienced by the child and their eating habits over a period of 2 wk. RESULTS: We find no significant difference in urinary IAG levels between the ASD children with GI problems and ASD children without GI problems. Although we see some difference between ASD children with GI problems and controls in mainstream schools with GI problems, the difference between non-autistic children with other developmental disorders and controls in mainstream schools is more significant so that any difference is not autism-specific. We find a strong correlation between bowel symptoms and diet problems in ASD children, especially idiosyncratic feeding behavior and we show that ASD children suffering from multiple bowel symptoms tend to be those who also have dietary problems. CONCLUSION: We found no evidence to support the hypothesis that children with ASD who suffer with bowel problems have increased levels of urinary IAG in comparison to children with ASD who do not have gastrointestinal problems.
BACKGROUND: An increase in urinary indolyl-3-acryloylglycine (IAG) has been reported in children with autism spectrum disorders (ASD) who suffer with bowel problems in comparison to ASDchildren without gastrointestinal (GI) problems. The case for dietary intervention for ASDchildren with GI symptoms might be strengthened were such a difference to be autism-specific. METHODS: Quantitative analysis of urinary IAG levels was performed for 53 children on the autism spectrum and 146 age-matched controls. The parents of each child were asked to provide information on bowel symptoms experienced by the child and their eating habits over a period of 2 wk. RESULTS: We find no significant difference in urinary IAG levels between the ASDchildren with GI problems and ASDchildren without GI problems. Although we see some difference between ASDchildren with GI problems and controls in mainstream schools with GI problems, the difference between non-autisticchildren with other developmental disorders and controls in mainstream schools is more significant so that any difference is not autism-specific. We find a strong correlation between bowel symptoms and diet problems in ASDchildren, especially idiosyncratic feeding behavior and we show that ASDchildren suffering from multiple bowel symptoms tend to be those who also have dietary problems. CONCLUSION: We found no evidence to support the hypothesis that children with ASD who suffer with bowel problems have increased levels of urinary IAG in comparison to children with ASD who do not have gastrointestinal problems.
Authors: Maria Valicenti-McDermott; Kathryn McVicar; Isabelle Rapin; Barry K Wershil; Herbert Cohen; Shlomo Shinnar Journal: J Dev Behav Pediatr Date: 2006-04 Impact factor: 2.225
Authors: Susan L Hyman; Patricia A Stewart; Jennifer Foley; Usa Cain; Robin Peck; Danielle D Morris; Hongyue Wang; Tristram Smith Journal: J Autism Dev Disord Date: 2016-01
Authors: M Parellada; M J Penzol; L Pina; C Moreno; E González-Vioque; G Zalsman; C Arango Journal: Eur Psychiatry Date: 2013-11-22 Impact factor: 5.361